Cardiac Mortality in Children and Adolescents with Hodgkin's Lymphoma: A Surveillance, Epidemiology and End Results Analysis

Abstract

The cumulative incidence of CSM in this population analysis of pediatric HL was 9.2%, with a steady decline over the past several decades. Adolescent patients at diagnosis and males were more likely to die of cardiac-related causes.

Pediatric Hodgkin Lymphoma, Version 3.2021

“…Given the long-term risks of the therapies for HL, including secondary cancers, cardiac toxicity, pulmonary toxicity, thyroid dysfunction, and reproductive issues, [46][47][48][49][50][51][52][53][54] patients should be followed up by an oncologist who is aware of these risks and complications, in coordination with the primary care provider, especially during the first 2 years after treatment (see PHL-6, page 739). The follow-up schedule should be individualized, depending on clinical circumstances such as patient's age, gender, stage of disease, and initial treatment modality.…”

Long‐term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors

“…The first peak period of cHL is around the age of 20 to 30 years, and the second peak is around the age of 50 to 70 years 21 . Age at diagnosis, race, sex, Ann Arbor stage, and treatment are closely related to CVD in patients with cHL 18,22,23,24,25 . Several studies showed that the cumulative incidence of CVD mortality increased after long‐term follow‐up 10,26,27 .…”

“…Most previous studies involving cardiovascular side effects in cHL focused only on children or young adults, and few studies observed patients diagnosed at all ages. [18][19][20] The first peak period of cHL is around the age of 20 to 30 years, and the second peak is around the age of 50 to 70 years. 21 Age at diagnosis, race, sex, Ann Arbor stage, and treatment are closely related to CVD in patients with Cancer September 15, 2022 cHL.…”

“…21 Age at diagnosis, race, sex, Ann Arbor stage, and treatment are closely related to CVD in patients with Cancer September 15, 2022 cHL. 18,22,23,24,25 Several studies showed that the cumulative incidence of CVD mortality increased after long-term follow-up. 10,26,27 Few studies examined competing risks of the outcomes of patients with cHL by the risk factors mentioned previously.…”

“…Minimizing long‐term cardiovascular complications and mortality appears to be a particularly important strategy to improve the quality of life of cHL survivors. Most previous studies involving cardiovascular side effects in cHL focused only on children or young adults, and few studies observed patients diagnosed at all ages 18‐20 . The first peak period of cHL is around the age of 20 to 30 years, and the second peak is around the age of 50 to 70 years 21 .…”